Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (NCT06276491)
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 15 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- City of Hope — Duarte, California
- Stanford — Palo Alto, California
- University of California — San Francisco, California
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Karmanos Cancer Institute — Detroit, Michigan
- University of Minnesota — Minneapolis, Minnesota
- The John Theruer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- Icahn School of Medicine at Mount Sinai — New York, New York
- Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York
- The Ohio State University — Columbus, Ohio
- OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- SCRI Oncology Partners — Nashville, Tennessee
- University of Virginia — Charlottesville, Virginia
- AZ Groeninge — Kortrijk,
- CHU de Liege — Liège,
- Herlev Gentofte Hospital — Herlev,
- NEXT Oncology - Hospital Quironsalud — Barcelona,
- NEXT Oncology - Hospital Quironsalud — Madrid,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer — Houston, Texas
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy — Miami, Florida
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.